Navigation Links
Recipient of Melanoma Drug in Development Celebrates Two Cancer-Free Years
Date:10/16/2007

KNOXVILLE, Tenn., Oct. 16 /PRNewswire/ -- When eighty-six-year-old Keith Hora went to see Dr. Peter Hersey, a medical oncologist and professor at the University of Newcastle in Australia, he was told he only had three to six months to live. Hora had been diagnosed with stage III melanoma, one of the most difficult to treat forms of cancer.

"Mr. Hora had multiple melanoma reoccurrences in the previously treated area of his face and nothing was helping him, including multiple surgeries to remove the tumors as well as radiation therapy," recalls Dr. Hersey, a fifteen-year member of the World Health Organization's committee on Melanoma. "His tumors kept returning."

Hora was included in a Phase 1 clinical trial of PV-10 conducted by Dr. Hersey. The trials were sponsored by Knoxville, TN-based Provectus Pharmaceuticals. PV-10 is a small molecule oncology agent being investigated by Provectus for treatment of melanoma and other focal forms of cancer.

"When it is injected into tumor tissue, the drug concentrates in the tumor at cytotoxic levels while quickly dissipating from healthy tissue," says Dr. Hersey. "This makes it safer and more effective than some other therapies."

Hora was treated in late 2005 and recalled getting the good news a few weeks later during an ultrasound follow-up that determined the tumors were shrinking. "After being cancer-free for two years, I feel like jumping over a moon," says Hora.

Provectus has begun the next round of testing intended to demonstrate definitively the efficacy of PV-10. The Phase 2 trial will treat up to eighty Stage III/IV melanoma patients at seven or more sites in Australia and the U.S. While PV-10 is currently undergoing clinical trials to treat melanoma and breast cancer, in pre-clinical testing the drug has been shown to kill many other types of cancer. Additional clinical testing for treatment of primary and metastatic liver cancers is expected to begin later this year or early in 2008.

For more information, log on to http://www.pvct.com.


'/>"/>
SOURCE Provectus Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting
2. IDM Pharma Presents Preliminary Results from Phase II UVIDEM Melanoma Vaccine Clinical Trial
3. Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
4. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
5. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
6. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
7. SciClone and Sigma-Tau Report Thymalfasin Meets Primary Endpoint in Phase 2 Malignant Melanoma Trial
8. Inovio Biomedicals DNA Delivery Technology Shows Safety and Enhances Gene Expression & Tumor Responses in Interim Melanoma Clinical Study Results
9. Multiferon Shows Potent Activity in Preventing the Progression of Malignant Melanoma; Study to be Published
10. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
11. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... 7, 2016  Urinary catheters are used for ... other urological disorders. Urinary catheters include indwelling (Foley) ... Indwelling or Foley catheter is a flexible tube ... catheter is inserted into the bladder through the ... balloon attachment at one end of the catheter ...
(Date:12/7/2016)... YORK , Dec. 7, 2016 Global ... This report on the global hospital linen supply and ... of this market on a global and regional level. ... forecast for the period between 2015 and 2024 based ... the dynamics of the market along with their impact ...
(Date:12/7/2016)... , Dec. 7, 2016 A new investigational drug ... human clinical trials in search of the world,s first treatment ... publication of research findings today in the journal ... will be a watershed moment for millions of people living ... director of Van Andel Research Institute,s Center ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... ... serve communities in and around the greater Phoenix metropolitan region, is announcing a ... , The mission of the Homeless Youth Connection is to promote community awareness ...
(Date:12/8/2016)... ... December 08, 2016 , ... Bill ... and business owners in and around central Kansas, is joining the Youth Horizons ... in the region. , Headquartered in Wichita, Youth Horizons works to empower area ...
(Date:12/7/2016)... Wisconsin (PRWEB) , ... December 07, 2016 , ... Kenall ... extraordinary new MedMaster™ MPCNGX . The MPCNGX is a multi-function, sealed, LED luminaire ... right amount of light where and when it’s needed. , A 2’ ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... up with a schizophrenic mother in a unique, personal perspective through animation. ... treating trauma and addictive disorders at her private psychotherapy practice. Sheri’s mother, Pearl, ...
(Date:12/7/2016)... ... December 07, 2016 , ... Castle Dermatology Institute is now offering liquid ... a more youthful appearance to the face. Dr. Peyman Ghasri and Dr. Pedram Ghasri, ... of other treatments, to rejuvenate and renew the facial appearance. , Sculptra is ...
Breaking Medicine News(10 mins):